Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000482690 | SCV000571167 | likely benign | not provided | 2018-02-02 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV002063783 | SCV002420717 | likely benign | RASopathy | 2025-01-12 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002496870 | SCV002802510 | likely benign | Melorheostosis; Noonan syndrome 1; Cardiofaciocutaneous syndrome 3 | 2022-03-30 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003488628 | SCV004241071 | likely benign | not specified | 2023-12-13 | criteria provided, single submitter | clinical testing | Variant summary: MAP2K1 c.291+14_291+20delins15 alters a nucleotide located at a position not widely known to affect splicing. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant was absent in 1608680 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.291+14_291+20delins15 in individuals affected with Cardiofaciocutaneous Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. Three submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as likely benign. Based on the evidence outlined above, the variant was classified as likely benign. |